MicroRNAs (miRNAs) are small noncoding RNAs that control the expression of around 60% of the human protein-coding genes. In the past decade, deregulation of miRNAs (by expression and/or function) has been associated with the pathogenesis, progression and prognosis of different diseases, including leukemia. The number of discovered genes encoding miRNAs has risen exponentially in this period, but the numbers of miRNA-target genes discovered and validated lag far behind. Scientists have gained more in-depth knowledge of the basic mechanism of action of miRNAs, but the main challenge still remaining is the identification of direct targets of these important 'micro-players', to understand how they fine-tune so many biological processes in both healthy and diseased tissue. Many technologies have been developed in the past few years, some with more potential than others, but all with their own pros and cons. Here, we review the most common and most potent computational and experimental approaches for miRNA-target gene discovery and discuss how the hunting of targets is challenging but possible by taking the experimental limitations in consideration and choosing the correct cellular context for identifying relevant target genes.
INTRODUCTION
In 1993, two seminal reports 1,2 described the discovery of posttranscriptional gene silencing by antisense RNA-RNA interaction in nematodes, introducing a new mechanism of gene expression regulation in metazoan. In a short time, several more small noncoding RNAs were identified in nematodes and insects, 3, 4 and it was discovered that most of these molecules, termed 'microRNAs' (miRNAs), were highly conserved in many other species. 5 The miRNAs are involved in the translational regulation of around 60% of the human protein-coding genes, 6 and it is now well established that miRNAs control different cellular processes such as apoptosis, 7 ,8 proliferation 9,10 and differentiation. 11 Altered expression of miRNAs correlates with initiation and progression of many diseases and malignancies 7, 8, [12] [13] [14] including different types of leukemia; 13, [15] [16] [17] as such, miRNAs are associated with the prognosis of leukemic patients by controlling the level of sensitivity to cytotoxic drugs, [18] [19] [20] growth rate 7 and differentiation. 21, 22 GLOBAL ACTS, LOCAL TASKS According to the latest version of the miRNA database (miRBase 18, released on November 2011, University of Manchester, UK), there are 18 226 miRNA hairpin precursor entries encoding 21 643 mature miRNA sequences in 168 species (http://mirbase.org/index. shtml). The fine-tuning of basic cellular activities (for example, growth, apoptosis and differentiation) by miRNAs implicates the contribution of these tiny molecules in biological activities all over the body. 7, 11, 23 The miRNAs with proven contribution to general biological processes are summarized in Table 1 . In addition, miRNA profiling studies reveal unique expression signatures discriminative for different types of healthy human tissues. 13, 24 It has been shown that miRNA biogenesis, expression level and function are differentially controlled in tissues of different origin. 25 As an example, both miR-221 and miR-222 inhibit proliferation in erythroblastic leukemia cells, whereas the same miRNAs act in an opposite way in many solid malignancies, promoting proliferation and survival. 26 RNA-binding proteins (RBPs) that can either induce or suppress the expression of miRNAs and control their binding to their targets are putative important regulators of tissue-specific miRNA expression and function. 25, 27, 28 TARGET DISCOVERY, THE BIGGEST CHALLENGE Nowadays, generating miRNA expression signatures, the correlation of these expression patterns to disease stage and progression, and even discovery of new miRNAs is technically easily feasible. 29, 30 Yet, the most challenging question is how to recognize direct target genes of miRNAs of interest. Several computational and experimental approaches toward miRNA target gene discovery have been developed and tested, which take into account the biological processing and the function of miRNAs, as well as the complex target gene-binding parameters. 31, 32 COMPUTATIONAL TARGET PREDICTION Partial Watson-Crick complementarity of a miRNA to its target sequence is mandatory for binding. 33, 34 Based on this simple but important fact, different computational algorithms have been developed to predict potential binding sites of a specific miRNA. 34 The majority of these target prediction tools are based on the stringent pairing of the target sequence within the mRNA to the 'seed' sequence, that is, the nucleotides 2-7 of the 5' end of the B22 nucleotide sequence encoding the mature miRNA. 35 This area is the most conserved part of metazoan miRNAs; prediction based on complete seed base-paring significantly decreases the number of false-positive results. 33, 36 Most of these prediction algorithms are limited to browse the 3 0 untranslated regions (UTRs) of human mRNAs. However, this is not the only binding region for miRNAs, as there are also sites located in 5 0 UTR or even within the coding DNA sequence of mRNAs. [37] [38] [39] In addition, perfect seed base-pairing is not always an essential factor for miRNA-mRNA binding; in the presence of seed sequence mismatch, miRNA-mRNA binding may also happen through additional compensatory base-pairing of the 3 0 part of miRNA to its target sequence. [39] [40] [41] [42] The partial complementarity of miRNAs to their target genes together with the different forms of seed mismatch-pairing represent one of the major challenges in miRNA target recognition. Figure 1 represents major binding possibilities of miRNA-target mRNA.
The most common prediction algorithms and their characteristics are listed in Table 2 . Tools using similar powerful prediction characteristics, such as the mandatory stringent seed base-pairing used in TargetScan, PicTar and EIMMo3, have similar but not completely identical prediction results. Usage of different UTR databases, as well as diverse internal criteria, can be the reason of this dissimilarity. In addition, these prediction algorithms also vary in the individual ranking systems; for example, the direct target of miR-196b, HOXC8, 43 is ranked at position 1 in TargetScan and PicTar, at position 2 in EIMMo3 and at position 70 in PITA. This variation in prediction gives the scientists the ability to combine knowledge of disease biology and predicted targets to select target genes of interest. However, it can be difficult to select the best potential candidates from the long prediction lists. As an example, TargetScan, the most frequently used and referenced prediction algorithm, predicts three of the validated target genes of the let-7 family (HMGA2, LIN28B and TRIM71) among the top five predicted target genes, whereas other proven targets of human let-7 family, NRAS and ITGB3, are ranked at position 143 and 393, respectively. Moreover, TargetScan predicts only one of the nine validated direct targets of miR-133a (FSCN1), albeit ranked at position 402. This poor prediction accuracy is observed for other computational prediction programs as well. Therefore, referring to only one target prediction tool is a risky and biased approach.
The majority of the currently available miRNA target-prediction algorithms (except EIMMo3) are designed to predict possible Hunting of miRNA targets F Akbari Moqadam et al targets of only one miRNA. However, in some cases, several miRNAs simultaneously bind to and subsequently control the target mRNA. The combination of miRNAs then determines if the target gene is translated to protein. 44 The miRNA multiplex phenomenon preludes also challenges in designing functional experiments and requires the development of multicistronic expression vectors to overexpress several miRNAs simultaneously. 45 
SPOTLIGHT

EXPERIMENTAL TARGET IDENTIFICATION
Although development of computational prediction tools was a great step forward in miRNA target gene discovery, the percentage of false-positive and -negative findings is substantial. Therefore, these tools are mostly used to narrow down the list of potential targets, as well as to support correlation studies between miRNA and mRNA/protein expression levels as an indication for miRNA targets. True targets of miRNAs can only be validated by different experimental procedures in the cell type of interest. A summary of the potential possibilities to discover miRNA target genes based on biogenesis and function of miRNAs are shown in Figure 2 .
Gene expression correlation studies An inverse correlation between expression level of miRNAs and mRNAs may indicate potential targets of miRNAs that are degraded upon miRNA-mRNA bindings. Therefore, changes in the mRNA levels after functional interference with miRNAs (for example, ectopic induction or repression) may be indicative for targets regulated by miRNAs of interest (Figure 2a ). Using this strategy, it has been shown that overexpression of miR-1 and miR-124a in HeLa cells downregulates the expression of more than 100 mRNAs. 46 Subsequent analyses showed that the majority of these downregulated mRNAs contain the seed complementary sequences in their 3 0 UTR regions associated with the overexpressed miRNAs. 46 The analyses also revealed that overexpression of tissue-specific miRNAs (miR-1, muscle specific, and miR-124a, brain specific) in a different context (HeLa cells, cervical cancer) partially turned the mRNA expression profile of the HeLa cells into that of the tissues that normally expressed those miRNAs. 46 This confirms the important role of miRNAs in tissue development and maintenance. Rapidly, similar reports on miRNA target discovery were published by other groups. 47, 48 Limited by the availability of tumor-representing cell line models, most of the overexpression studies are performed in a cell type Site numbers, the number of potential binding sites in the 3' UTR of the target mRNA; Site type, the complementarity of the miRNA, especially of its seed sequence, to the target mRNA (for example, 8mer and others or 3 0 compensatory); Site context and score, sum of the contribution of the following six features: site type, contribution of 3 0 pairing, local AU enrichment, site location, target site abundance and seed-pairing stability, 125 Wobble, non-Watson-Crick basepairing between two nucleotides of RNA molecules which can be G:U, I (inosine):A, I:C and I:U. This can potentially result in missing tissue-specific target genes. Furthermore, most of the enforced expression studies will result in a supraphysiological increase in miRNA levels, augmenting the chance for off-target effects and false-positive read outs. 48, 49 The disadvantages of miRNA overexpression strategies can be avoided by miRNA-silencing methods; these are based on antisense oligonucleotides that scavenge the miRNA of interest by forming miRNA/anti-miR duplexes. 50 However, the antisense (anti-miR) sequence may not be specific enough to distinguish between similar miRNAs like miR-196a and miR-196b that only differ in one nucleotide. A caveat is that these miRNA/ anti-miR duplexes prevent the scavenging effect to be quantified as the duplex is not easily degraded and does not result into measurable reduction of miRNA level. Recent development in overexpressing RNA sequences complementary to miRNA seed sequence, known as 'miRNA sponges', might be the solution to create a proper and measurable silencing tool. 51 
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Biochemical approaches
The specificity of target discovery may be increased by the analysis of miRNA-mRNA complexes isolated using co-immunoprecipitation of RNA-induced silencing complex (RISC) proteins like argonaute (AGO) [52] [53] [54] [55] (Figure 2b ). This can be done by using epitope-tagged AGO 53, 56 or highly specific monoclonal antibodies Figure 2 . Common available approaches toward miRNA target identification: currently available approaches in miRNA target identification have been designed depending on biological biogenesis and function of miRNAs. Integration and prediction studies: (a) finding significant (mainly inverse) correlations between miRNA and mRNA expression levels in combination with prediction of target genes by combining output of several target prediction algorithms. Experimental interaction studies: (b) co-immunoprecipitation of miRNA-mRNA complexes by RISC (AGO) precipitation with or without prior exposure to UV light (HITS-CLIP and PAR-CLIP); (c): selecting for mRNAs bound to taggedmiRNAs; (d): parallel analysis of RNA ends (PARE) possible after cleavage of target mRNA; (e): using the miRNAs as primers for cDNA synthesis after RISC and other proteins (other RBPs) have been removed; (f ): polysome profiling in which ribosome-bound mRNAs serve as input for gene expression arrays or sequencing. Protein synthesis studies: (g): aberrant de novo protein synthesis detected by using stable isotope labeled amino acids (SILAC); (h): aberrant expression levels detected by changes in Cy3/Cy5 labeling of proteins followed by separation using twodimensional fluorescence difference gel electrophoresis (2D-DIGE); (i): measuring expression levels of selected proteins using reverse-phase protein array (RPPA); (j): classical approach to analyze expression of one putative target gene both on protein (for example, by western blot) and mRNA level (for example, by Taqman qRT-PCR) after modulation specific miRNA expression levels. Target validation studies: (k): the specificity of the miRNA-mRNA interaction is mostly validated by 3 0 UTR binding assessment using luciferase reporter assays.
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Hunting of miRNA targets F Akbari Moqadam et al against endogenous AGO proteins. 52, 57 The precipitated fraction can then be analyzed for captured mRNA sequences by gene expression arrays or deep sequencing. 52, 57 The precipitated mRNAs are 40-180-fold enriched for complementary seed sequences of overexpressed miRNAs, which is significantly higher than expected by chance. 54 In contrast to gene expression correlation analyses, purifying the active miRNAmRNA complexes enables the discovery of target genes that can be regulated by both mRNA degradation and translational inhibition. However, this immunoprecipitation approach does not necessarily recapitulate the in vivo miRNA-mRNA interaction as different RBPs, including AGO, may artificially and nonspecifically associate with mRNAs upon cell lysis. 57 In addition, the binding of miRNA-mRNA can be too weak for an efficient co-immunoprecipitation. 58 To strengthen the interaction between miRNA-mRNA duplexes, RNA/protein complexes are crosslinked using ultraviolet irradiation before co-immunoprecipitation; this is subsequently followed by deep sequencing of the purified fractions (Figure 2b ). This so-called high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP) method was tested to identify miRNA targets in a mouse brain cell line 59 and Caenorhabditis elegans. 60 HITS-CLIP may be a powerful strategy to identify biologically relevant targets of miRNAs in vivo as exemplified by the discovery of MMP2 as the target of miR-9. 61 However, the efficiency of ultraviolet irradiation to crosslink RNAprotein complexes is being controversially discussed. 56 Recently, a new technique has been developed, called photoactivableribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP), that aims at discovering the interaction between RBPs with cellular RNAs. 62 PAR-CLIP is based on incorporating photoreactive ribonucleoside analogs like 4-thiouridine (4-SU) and/or 6-thioguanosine (6-SG) into newly synthesized RNAs of living cells. UV irradiation of the cells lead to efficient crosslinking, which is followed by immunoprecipitation of the RBPs of interest. The bound mRNA sequences can be converted to cDNA and identified using high-throughput sequencing or gene expression profiling. Fourteen target genes of Epstein-Barr virus miRNAs have been successfully identified and validated using PAR-CLIP. 63 A major caveat for miRNA-mRNA and AGO/RISC co-immunoprecipitation studies is the fact that every miRNA-mRNA duplex has a similar chance to precipitate. Therefore, the share of miRNA-mRNA complexes of interest can only become discriminative upon overexpression or inhibition of desired miRNA before co-immunoprecipitation.
Applying tagged miRNAs can increase the specificity of immunoprecipitation (Figure 2c ). For example, transfection of cells with biotin-labeled miRNAs and subsequently capturing the associated miRNA-mRNAs duplexes by streptavidin beads result in an enriched fraction for complexes of interest. This method has been first optimized in the fruit fly Drosophila melanogaster 64 and then applied in mouse E14 embryonic stem cells, as well as HepG2 cells, confirming successful enrichment of previously discovered target genes of miR-10a and miR-122, respectively. 39, 65 The streptavidin-mediated capture of biotinylated miRNA-mRNA complexes has been successfully used to discover a new target gene for miR-122 (PRKRA) and technical improvements in this methodology even yielded 14 new target genes for miR-34a (a.o. ARAF, PIK3R2, MEK1, PLK1 and SMAD4), which were all confirmed as true targets of miR-34a. 65, 66 This indicates the strength and value of this approach in the hunting of true miR-targets. In addition, a new regulating role of miR-10a was discovered showing that this miRNA targets the 5 0 UTR of ribosomal protein mRNAs resulting in an increase instead of the expected decrease of protein translation. 39 Another tag successfully employed for miRNA target discovery in C. elegans and zebrafish is digoxigenin. 67, 68 Albeit these tagged-miRNA approaches can yield informative data, one should keep in mind that overexpression of labeled miRNAs may potentially induce off-target effects and/or the 3 0 tag may affect the strength of miRNA-mRNA binding due to sterical hindrance.
No additional chemical modifications of miRNAs are needed for the parallel analysis of RNA ends (PARE) method. This novel method has been designed to identify the cleaved mRNAs that arise upon miRNA binding (Figure 2d ). In principle, polyadenylated RNAs are extracted and an RNA adaptor is ligated to the 5 0 end of the cleaved mRNAs. Thereafter, the poly-A tail of mRNAs serve as a primer for cDNA synthesis followed by PCR to amplify the cDNA. These products are further processed and used for highthroughput sequencing. 69 The readout sequences are matched with genome browser databases to identify the mRNAs that were cleaved upon overexpression of the miRNA of interest. 69 PARE method is restricted to the identification of mRNA targets that are degraded. Alternatively, a strong detergent can be used to remove RISC proteins that will expose the bound miRNAs to serve as primers for cDNA synthesis upon incubation with reverse transcriptase (Figure 2e) . The cDNA is then cloned and sequenced to identify target mRNAs that may be both targets of miRNA cleavage or translational inhibition. 70 So far, this method was only successfully applied in C. elegans and showed K10C3.4 being the direct target of let-7.
71 Recently, polysome profiling (Figure 2f ) has been suggested for the analysis of translationally active mRNAs. In this method, elongating ribosomes are trapped by cyclohexamide and mRNAs bound to ribosomes are isolated by sucrose gradient centrifugation. 72 Next, the ribosome-bound mRNAs are identified and quantified by gene expression microarrays and/or RNA sequencing.
Proteomic approaches Proteomic technologies may provide the most relevant opportunity for miRNA target discovery as a change in protein expression level is the ultimate effect of miRNA function. Stable isotope labeling of amino acids in cell culture (SILAC) may be a tool to identify affected proteins. 73, 74 Cells with a modulated level of a miRNA and those with a mock control are kept in culture in two different media, one containing normal and the other containing heavy isotopes of essential amino acids (often lysine and arginine). The difference in de novo protein synthesis is quantified by comparing the ratio of peak intensities of heavy and light isotopes by mass spectrometry (Figure 2g) . A ratio unequal to one indicates a gene that is either directly or indirectly controlled by the miRNA of interest. 75, 76 Target genes of miR-143, miR-155 and miR-373 have been identified using the SILAC-based proteomic approach. [77] [78] [79] A second proteomic approach is two-dimensional fluorescence difference gel electrophoresis (2D-DIGE; Figure 2h ). In this method, proteins extracted from cells under two different conditions (for example, miRNA and mock-transfected cells) are labeled with distinct fluorescent dyes (for example, Cy3 and Cy5) and separated by isoelectric focusing (first dimension) and molecular size (second dimension) gel electrophoresis. Differentially expressed proteins are identified based on the Cy3/Cy5 ratio, followed by excision out of gel, trypsinization and subsequent analyses by mass spectrometry. 80, 81 The excised spots still contain numerous different proteins and subsequent analysis of 3 0 UTR sequences of the identified candidate proteins for the presence of seed complement regions is required to help narrowing down the number of candidate targets.
Another method used is the analysis of protein expression levels by reverse-phase protein arrays (RPPA), for instance after exogenous manipulation of miRNA expression levels 81 ( Figure 2i ). However, this method is restricted to the availability of high-quality antibodies.
TARGET VALIDATION
After the identification of potential miRNA target genes, the physical binding of miRNA to candidate mRNAs and the subsequent translational modulation needs to be confirmed. The majority of target validation studies use a luciferase sequence
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Hunting of miRNA targets F Akbari Moqadam et al as a reporter followed by 3 0 UTR sequence of the candidate target gene. 82 A drop in luciferase activity upon overexpression of miRNA suggests a binding of the miRNA to its target 3 0 UTR mRNA sequence (Figure 2k ). It is important to include proper controls to test specificity of the miRNA-mRNA interaction, for example, a mock miRNA-mimic sequence and a mutant form of the target 3 0 UTR mRNA sequence that has lost the predicted binding sites for miRNA. [7] [8] [9] [10] 23 For this approach, oftentimes, cell lines are chosen due to their transfectability (for example, HEK293 cells); however, tissue-specific miRNA biogenesis and binding 25, 27, 28, 83 warrants to perform these studies in relevant cell line models resembling the tissue of origin. 7, 10, 23, 84 For instance, FBW7 was validated as target of miR-27a by a significant decrease in luciferase signal in MCF7 and U2OS cells, but not in the HEK293 cell line. 10 SUMMARY AND PERSPECTIVES Progress of our knowledge in miRNA biology provides a wide range of opportunities in computational and experimental miRNA target identification approaches, albeit each of them has its limitations. Computational target prediction algorithms are provisionary tools to draw-up a putative landscape of miRNA function. Next, experimental approaches should determine which predicted gene may be a true target for the miRNA. The most important issue is to use cell line models resembling the original tissue in which the miRNA of interest was identified. Tissue-specific miRNA biogenesis and expression of RBPs illustrate the importance of cell type in miRNA target gene discovery. Experimental artifacts induced by manipulation of the expression level of miRNAs and the limitation in availability of suitable representative cell line models can be circumvented by the analysis of genome-wide patient data sets. 19, 29, 85, 86 MiRNA, mRNA and/or protein expression data of different cohorts of patients can be integrated to discover biological and clinical relevant miRNA target genes. 86 Recently, the importance to analyze primary patient samples was even further emphasized upon the discovery that the 3 0 UTR of genes can be shortened upon alternative splicing in cancer, yielding disrupted miRNA function compared with healthy tissue. 87, 88 Current knowledge of miRNAs biogenesis and function point to a clinical value of miRNAs. Several ways in reprogramming the altered expression of miRNAs into its original healthy signature have been tested to treat the pathological behavior of the affected cells. Tumor growth inhibition in breast cancer cell lines by miR-21 knockdown 89 and sensitization of drug-resistant glioblastoma cells by downregulating miR-195 (ref. 90) are pivotal examples. Additionally, locked nucleic acid-modified antisense sequences against highly expressed miR-122 was successfully applied in African green monkeys with hypercholesterolemia as one of the first in vivo experiments of using anti-miRs, albeit in non-human primates. 91 The successful results of this experiment aiming at controlling the triglyceride and cholesterol level and disease manifestations with minimal side effects heralds a new field of research to develop more sensitive and powerful medications. Ongoing studies in developing more sensitive computational algorithms and in optimizing proteomic technologies for miRNA target recognition will further improve our understanding in miRNA function in healthy and diseased tissue. In the end, hunting of target genes of miRNAs will broaden our perspective of the role of miRNAs as a therapeutic tool.
